Protocol No. MSDC-0602K-C009NASH: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients with NASH (EMMINENCE™)
- Rinella, Mary Eugenia (PD/PI)
Project: Research project